Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $52.43

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and three have given a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $50.8571.

A number of research firms recently commented on IMUX. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Sunday, April 19th. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a report on Monday, May 4th. Guggenheim started coverage on shares of Immunic in a report on Tuesday, March 24th. They issued a “buy” rating and a $70.00 price target on the stock. raised shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target (up from $5.00) on shares of Immunic in a report on Thursday, April 30th.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently modified their holdings of IMUX. Nantahala Capital Management LLC purchased a new stake in shares of Immunic in the fourth quarter valued at about $2,337,000. Millennium Management LLC lifted its holdings in shares of Immunic by 544.6% in the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Laurion Capital Management LP lifted its holdings in shares of Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after purchasing an additional 2,000,000 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Immunic in the first quarter valued at about $1,020,000. Finally, Marshall Wace LLP lifted its holdings in shares of Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock valued at $541,000 after purchasing an additional 486,468 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Trading Down 3.5%

IMUX stock opened at $11.66 on Tuesday. The company has a market cap of $158.81 million, a P/E ratio of -2.09 and a beta of 1.20. Immunic has a 52 week low of $5.06 and a 52 week high of $15.10. The company’s 50-day moving average price is $11.45 and its 200 day moving average price is $8.66.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). On average, equities research analysts expect that Immunic will post -3.38 earnings per share for the current year.

Immunic News Roundup

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Immunic appointed veteran biopharmaceutical executive Michael W. Bonney as Chair of the Board, a move that may be viewed favorably because of his deep commercialization and leadership experience in multiple sclerosis and biotech. Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
• Neutral Sentiment: Multiple brokerage notes reiterated bullish ratings on Immunic, including HC Wainwright’s Buy rating and $22 price target, which suggests continued long-term optimism despite near-term risk.
• Negative Sentiment: HC Wainwright cut earnings estimates across several future periods, signaling expectations for larger losses than previously modeled. The firm reduced its FY2026 EPS estimate to ($7.02) from ($2.61), FY2027 to ($9.05) from ($6.01), FY2028 to ($5.88) from ($3.66), FY2029 to ($4.51) from ($2.36), and FY2030 to ($2.92) from ($1.08).
• Negative Sentiment: The analyst also lowered quarterly EPS forecasts for Q2 2026, Q3 2026, and Q4 2026, reinforcing concerns that Immunic may burn cash for longer than expected before reaching profitability.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.